Relationship between p63 and p53 expression in Merkel cell carcinoma and corresponding abnormalities in TP63 and TP53: a study and a proposal

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine carcinoma. Oncogenesis occurs via Merkel cell polyomavirus–mediated (MCPyV+) and/or ultraviolet radiation–associated (MCPyV−) pathways. Advanced clinical stage and an MCPyV− status are important adverse prognostic indicators....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Human pathology 2021-11, Vol.117, p.31-41
Hauptverfasser: DeCoste, Ryan C., Carter, Michael D., Pasternak, Sylvia, Fleming, Kirsten E., Gaston, Daniel, Legge, Alexandra, Ly, Thai Yen, Walsh, Noreen M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 41
container_issue
container_start_page 31
container_title Human pathology
container_volume 117
creator DeCoste, Ryan C.
Carter, Michael D.
Pasternak, Sylvia
Fleming, Kirsten E.
Gaston, Daniel
Legge, Alexandra
Ly, Thai Yen
Walsh, Noreen M.
description Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine carcinoma. Oncogenesis occurs via Merkel cell polyomavirus–mediated (MCPyV+) and/or ultraviolet radiation–associated (MCPyV−) pathways. Advanced clinical stage and an MCPyV− status are important adverse prognostic indicators. There is mounting evidence that p63 expression is a negative prognostic indicator in MCC and that it correlates with MCPyV− status. p63 is a member of the p53 family of proteins among which complex interactions occur. It has two main isoforms (proapoptotic TAp63 and oncogenic ΔNp63). Paradoxically, TAp63 predominates in MCC. To explore this quandary, we examined relationships between p63 and p53 expression and corresponding abnormalities in the TP63 and TP53 genes in MCC. A cohort of 26 MCCs (12 MCPyV+ and 14 MCPyV−) was studied. Comparative immunohistochemical expression of p63 and p53 was evaluated semiquantitatively (H scores) and qualitatively (aberrant patterns). The results were compared with genetic abnormalities in TP63 and TP53 via next-generation sequencing. p63 was positive in 73% of cases. p53 showed “wild-type” expression in 69%, with “aberrant” staining in 31%. TP63 mutations (predominantly low-level copy gains; 23% of cases) and mainly pathogenic mutations in TP53 (50% of cases) featured in the MCPyV− subset of cases. p63 expression correlated quantitatively with p53 expression and qualitatively with aberrant patterns of the latter. Increased expression of p63 and p53 and aberrant p53 staining correlated best with TP53 mutation. We propose that p63 expression (ie, proapoptotic TAp63) in MCC is most likely functionally driven as a compensatory response to defective p53 tumor suppressor activity. •In Merkel cell carcinoma (MCC), p63 expression is associated with a poor prognosis.•The proapoptotic TAp63 isoform of the protein predominates in MCC.•p63 expression in MCC correlates with increased/aberrant p53 expression.•p63 expression in MCC correlates with TP53 mutation.•p63 may be a functional marker of a disordered TP53/p53 system in MCC.
doi_str_mv 10.1016/j.humpath.2021.08.003
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2561918432</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0046817721001453</els_id><sourcerecordid>2580329580</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-274376d4f4af2200f9d2d90ee36fc0fa7c2b4aaf8d109a9fef2a0243ae7b31c3</originalsourceid><addsrcrecordid>eNqFkcuO1DAQRS0EYpqGTwBZYsMmwa-82KDRiJc0iBHqvVVtV2g3iR3sBJiP4J9xphsWbNhUSaVzb5V9CXnKWckZr18ey8MyTjAfSsEEL1lbMibvkQ2vpCha2Yn7ZMOYqouWN80FeZTSkTHOK1U9JBdSyY43qt2QX59xgNkFnw5uonucfyB6OtWSgrd0qiTFn1PElDJCnacfMX7FgRoccoFonA8j3LEmxMxNwVvnv1DY-xBHGNzsMK3C3c3Zc3dTyVcUaJoXe3s3ATrFMIUEw2PyoIch4ZNz35Ld2ze7q_fF9ad3H64urwujqm4uRKNkU1vVK-iFYKzvrLAdQ5R1b1gPjRF7BdC3lrMOuh57AUwoCdjsJTdyS16cbPPebwumWY8urU8Cj2FJWlQ173irpMjo83_QY1iiz8dlqmVSdGvdkupEmRhSitjrKboR4q3mTK9x6aM-x6XXuDRrdY4r656d3Zf9iPav6k8-GXh9AjD_xneHUSfj0Bu0LqKZtQ3uPyt-A_C7qVU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2580329580</pqid></control><display><type>article</type><title>Relationship between p63 and p53 expression in Merkel cell carcinoma and corresponding abnormalities in TP63 and TP53: a study and a proposal</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>DeCoste, Ryan C. ; Carter, Michael D. ; Pasternak, Sylvia ; Fleming, Kirsten E. ; Gaston, Daniel ; Legge, Alexandra ; Ly, Thai Yen ; Walsh, Noreen M.</creator><creatorcontrib>DeCoste, Ryan C. ; Carter, Michael D. ; Pasternak, Sylvia ; Fleming, Kirsten E. ; Gaston, Daniel ; Legge, Alexandra ; Ly, Thai Yen ; Walsh, Noreen M.</creatorcontrib><description>Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine carcinoma. Oncogenesis occurs via Merkel cell polyomavirus–mediated (MCPyV+) and/or ultraviolet radiation–associated (MCPyV−) pathways. Advanced clinical stage and an MCPyV− status are important adverse prognostic indicators. There is mounting evidence that p63 expression is a negative prognostic indicator in MCC and that it correlates with MCPyV− status. p63 is a member of the p53 family of proteins among which complex interactions occur. It has two main isoforms (proapoptotic TAp63 and oncogenic ΔNp63). Paradoxically, TAp63 predominates in MCC. To explore this quandary, we examined relationships between p63 and p53 expression and corresponding abnormalities in the TP63 and TP53 genes in MCC. A cohort of 26 MCCs (12 MCPyV+ and 14 MCPyV−) was studied. Comparative immunohistochemical expression of p63 and p53 was evaluated semiquantitatively (H scores) and qualitatively (aberrant patterns). The results were compared with genetic abnormalities in TP63 and TP53 via next-generation sequencing. p63 was positive in 73% of cases. p53 showed “wild-type” expression in 69%, with “aberrant” staining in 31%. TP63 mutations (predominantly low-level copy gains; 23% of cases) and mainly pathogenic mutations in TP53 (50% of cases) featured in the MCPyV− subset of cases. p63 expression correlated quantitatively with p53 expression and qualitatively with aberrant patterns of the latter. Increased expression of p63 and p53 and aberrant p53 staining correlated best with TP53 mutation. We propose that p63 expression (ie, proapoptotic TAp63) in MCC is most likely functionally driven as a compensatory response to defective p53 tumor suppressor activity. •In Merkel cell carcinoma (MCC), p63 expression is associated with a poor prognosis.•The proapoptotic TAp63 isoform of the protein predominates in MCC.•p63 expression in MCC correlates with increased/aberrant p53 expression.•p63 expression in MCC correlates with TP53 mutation.•p63 may be a functional marker of a disordered TP53/p53 system in MCC.</description><identifier>ISSN: 0046-8177</identifier><identifier>EISSN: 1532-8392</identifier><identifier>DOI: 10.1016/j.humpath.2021.08.003</identifier><identifier>PMID: 34391748</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Aged ; Aged, 80 and over ; Bioinformatics ; Cancer ; Carcinoma, Merkel Cell - genetics ; Carcinoma, Merkel Cell - metabolism ; Carcinoma, Merkel Cell - pathology ; Cell cycle ; Female ; Humans ; Male ; Medical prognosis ; Merkel cell carcinoma ; Middle Aged ; Morphology ; Mutation ; Next-generation sequencing ; p53 ; p63 ; Protein expression ; Protein Isoforms ; Proteins ; Skin cancer ; Skin Neoplasms - genetics ; Skin Neoplasms - metabolism ; Skin Neoplasms - pathology ; TP53 ; TP63 ; Transcription Factors - biosynthesis ; Transcription Factors - genetics ; Tumor Suppressor Protein p53 - biosynthesis ; Tumor Suppressor Protein p53 - genetics ; Tumor Suppressor Proteins - biosynthesis ; Tumor Suppressor Proteins - genetics ; Tumors ; Variables</subject><ispartof>Human pathology, 2021-11, Vol.117, p.31-41</ispartof><rights>2021 Elsevier Inc.</rights><rights>Copyright © 2021 Elsevier Inc. All rights reserved.</rights><rights>2021. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-274376d4f4af2200f9d2d90ee36fc0fa7c2b4aaf8d109a9fef2a0243ae7b31c3</citedby><cites>FETCH-LOGICAL-c459t-274376d4f4af2200f9d2d90ee36fc0fa7c2b4aaf8d109a9fef2a0243ae7b31c3</cites><orcidid>0000-0003-2841-8057 ; 0000-0002-9246-4317 ; 0000-0003-3205-0216 ; 0000-0002-7363-3509 ; 0000-0001-7586-9008</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0046817721001453$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34391748$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DeCoste, Ryan C.</creatorcontrib><creatorcontrib>Carter, Michael D.</creatorcontrib><creatorcontrib>Pasternak, Sylvia</creatorcontrib><creatorcontrib>Fleming, Kirsten E.</creatorcontrib><creatorcontrib>Gaston, Daniel</creatorcontrib><creatorcontrib>Legge, Alexandra</creatorcontrib><creatorcontrib>Ly, Thai Yen</creatorcontrib><creatorcontrib>Walsh, Noreen M.</creatorcontrib><title>Relationship between p63 and p53 expression in Merkel cell carcinoma and corresponding abnormalities in TP63 and TP53: a study and a proposal</title><title>Human pathology</title><addtitle>Hum Pathol</addtitle><description>Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine carcinoma. Oncogenesis occurs via Merkel cell polyomavirus–mediated (MCPyV+) and/or ultraviolet radiation–associated (MCPyV−) pathways. Advanced clinical stage and an MCPyV− status are important adverse prognostic indicators. There is mounting evidence that p63 expression is a negative prognostic indicator in MCC and that it correlates with MCPyV− status. p63 is a member of the p53 family of proteins among which complex interactions occur. It has two main isoforms (proapoptotic TAp63 and oncogenic ΔNp63). Paradoxically, TAp63 predominates in MCC. To explore this quandary, we examined relationships between p63 and p53 expression and corresponding abnormalities in the TP63 and TP53 genes in MCC. A cohort of 26 MCCs (12 MCPyV+ and 14 MCPyV−) was studied. Comparative immunohistochemical expression of p63 and p53 was evaluated semiquantitatively (H scores) and qualitatively (aberrant patterns). The results were compared with genetic abnormalities in TP63 and TP53 via next-generation sequencing. p63 was positive in 73% of cases. p53 showed “wild-type” expression in 69%, with “aberrant” staining in 31%. TP63 mutations (predominantly low-level copy gains; 23% of cases) and mainly pathogenic mutations in TP53 (50% of cases) featured in the MCPyV− subset of cases. p63 expression correlated quantitatively with p53 expression and qualitatively with aberrant patterns of the latter. Increased expression of p63 and p53 and aberrant p53 staining correlated best with TP53 mutation. We propose that p63 expression (ie, proapoptotic TAp63) in MCC is most likely functionally driven as a compensatory response to defective p53 tumor suppressor activity. •In Merkel cell carcinoma (MCC), p63 expression is associated with a poor prognosis.•The proapoptotic TAp63 isoform of the protein predominates in MCC.•p63 expression in MCC correlates with increased/aberrant p53 expression.•p63 expression in MCC correlates with TP53 mutation.•p63 may be a functional marker of a disordered TP53/p53 system in MCC.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bioinformatics</subject><subject>Cancer</subject><subject>Carcinoma, Merkel Cell - genetics</subject><subject>Carcinoma, Merkel Cell - metabolism</subject><subject>Carcinoma, Merkel Cell - pathology</subject><subject>Cell cycle</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Merkel cell carcinoma</subject><subject>Middle Aged</subject><subject>Morphology</subject><subject>Mutation</subject><subject>Next-generation sequencing</subject><subject>p53</subject><subject>p63</subject><subject>Protein expression</subject><subject>Protein Isoforms</subject><subject>Proteins</subject><subject>Skin cancer</subject><subject>Skin Neoplasms - genetics</subject><subject>Skin Neoplasms - metabolism</subject><subject>Skin Neoplasms - pathology</subject><subject>TP53</subject><subject>TP63</subject><subject>Transcription Factors - biosynthesis</subject><subject>Transcription Factors - genetics</subject><subject>Tumor Suppressor Protein p53 - biosynthesis</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tumor Suppressor Proteins - biosynthesis</subject><subject>Tumor Suppressor Proteins - genetics</subject><subject>Tumors</subject><subject>Variables</subject><issn>0046-8177</issn><issn>1532-8392</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkcuO1DAQRS0EYpqGTwBZYsMmwa-82KDRiJc0iBHqvVVtV2g3iR3sBJiP4J9xphsWbNhUSaVzb5V9CXnKWckZr18ey8MyTjAfSsEEL1lbMibvkQ2vpCha2Yn7ZMOYqouWN80FeZTSkTHOK1U9JBdSyY43qt2QX59xgNkFnw5uonucfyB6OtWSgrd0qiTFn1PElDJCnacfMX7FgRoccoFonA8j3LEmxMxNwVvnv1DY-xBHGNzsMK3C3c3Zc3dTyVcUaJoXe3s3ATrFMIUEw2PyoIch4ZNz35Ld2ze7q_fF9ad3H64urwujqm4uRKNkU1vVK-iFYKzvrLAdQ5R1b1gPjRF7BdC3lrMOuh57AUwoCdjsJTdyS16cbPPebwumWY8urU8Cj2FJWlQ173irpMjo83_QY1iiz8dlqmVSdGvdkupEmRhSitjrKboR4q3mTK9x6aM-x6XXuDRrdY4r656d3Zf9iPav6k8-GXh9AjD_xneHUSfj0Bu0LqKZtQ3uPyt-A_C7qVU</recordid><startdate>202111</startdate><enddate>202111</enddate><creator>DeCoste, Ryan C.</creator><creator>Carter, Michael D.</creator><creator>Pasternak, Sylvia</creator><creator>Fleming, Kirsten E.</creator><creator>Gaston, Daniel</creator><creator>Legge, Alexandra</creator><creator>Ly, Thai Yen</creator><creator>Walsh, Noreen M.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2841-8057</orcidid><orcidid>https://orcid.org/0000-0002-9246-4317</orcidid><orcidid>https://orcid.org/0000-0003-3205-0216</orcidid><orcidid>https://orcid.org/0000-0002-7363-3509</orcidid><orcidid>https://orcid.org/0000-0001-7586-9008</orcidid></search><sort><creationdate>202111</creationdate><title>Relationship between p63 and p53 expression in Merkel cell carcinoma and corresponding abnormalities in TP63 and TP53: a study and a proposal</title><author>DeCoste, Ryan C. ; Carter, Michael D. ; Pasternak, Sylvia ; Fleming, Kirsten E. ; Gaston, Daniel ; Legge, Alexandra ; Ly, Thai Yen ; Walsh, Noreen M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-274376d4f4af2200f9d2d90ee36fc0fa7c2b4aaf8d109a9fef2a0243ae7b31c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bioinformatics</topic><topic>Cancer</topic><topic>Carcinoma, Merkel Cell - genetics</topic><topic>Carcinoma, Merkel Cell - metabolism</topic><topic>Carcinoma, Merkel Cell - pathology</topic><topic>Cell cycle</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Merkel cell carcinoma</topic><topic>Middle Aged</topic><topic>Morphology</topic><topic>Mutation</topic><topic>Next-generation sequencing</topic><topic>p53</topic><topic>p63</topic><topic>Protein expression</topic><topic>Protein Isoforms</topic><topic>Proteins</topic><topic>Skin cancer</topic><topic>Skin Neoplasms - genetics</topic><topic>Skin Neoplasms - metabolism</topic><topic>Skin Neoplasms - pathology</topic><topic>TP53</topic><topic>TP63</topic><topic>Transcription Factors - biosynthesis</topic><topic>Transcription Factors - genetics</topic><topic>Tumor Suppressor Protein p53 - biosynthesis</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tumor Suppressor Proteins - biosynthesis</topic><topic>Tumor Suppressor Proteins - genetics</topic><topic>Tumors</topic><topic>Variables</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DeCoste, Ryan C.</creatorcontrib><creatorcontrib>Carter, Michael D.</creatorcontrib><creatorcontrib>Pasternak, Sylvia</creatorcontrib><creatorcontrib>Fleming, Kirsten E.</creatorcontrib><creatorcontrib>Gaston, Daniel</creatorcontrib><creatorcontrib>Legge, Alexandra</creatorcontrib><creatorcontrib>Ly, Thai Yen</creatorcontrib><creatorcontrib>Walsh, Noreen M.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Human pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DeCoste, Ryan C.</au><au>Carter, Michael D.</au><au>Pasternak, Sylvia</au><au>Fleming, Kirsten E.</au><au>Gaston, Daniel</au><au>Legge, Alexandra</au><au>Ly, Thai Yen</au><au>Walsh, Noreen M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Relationship between p63 and p53 expression in Merkel cell carcinoma and corresponding abnormalities in TP63 and TP53: a study and a proposal</atitle><jtitle>Human pathology</jtitle><addtitle>Hum Pathol</addtitle><date>2021-11</date><risdate>2021</risdate><volume>117</volume><spage>31</spage><epage>41</epage><pages>31-41</pages><issn>0046-8177</issn><eissn>1532-8392</eissn><abstract>Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine carcinoma. Oncogenesis occurs via Merkel cell polyomavirus–mediated (MCPyV+) and/or ultraviolet radiation–associated (MCPyV−) pathways. Advanced clinical stage and an MCPyV− status are important adverse prognostic indicators. There is mounting evidence that p63 expression is a negative prognostic indicator in MCC and that it correlates with MCPyV− status. p63 is a member of the p53 family of proteins among which complex interactions occur. It has two main isoforms (proapoptotic TAp63 and oncogenic ΔNp63). Paradoxically, TAp63 predominates in MCC. To explore this quandary, we examined relationships between p63 and p53 expression and corresponding abnormalities in the TP63 and TP53 genes in MCC. A cohort of 26 MCCs (12 MCPyV+ and 14 MCPyV−) was studied. Comparative immunohistochemical expression of p63 and p53 was evaluated semiquantitatively (H scores) and qualitatively (aberrant patterns). The results were compared with genetic abnormalities in TP63 and TP53 via next-generation sequencing. p63 was positive in 73% of cases. p53 showed “wild-type” expression in 69%, with “aberrant” staining in 31%. TP63 mutations (predominantly low-level copy gains; 23% of cases) and mainly pathogenic mutations in TP53 (50% of cases) featured in the MCPyV− subset of cases. p63 expression correlated quantitatively with p53 expression and qualitatively with aberrant patterns of the latter. Increased expression of p63 and p53 and aberrant p53 staining correlated best with TP53 mutation. We propose that p63 expression (ie, proapoptotic TAp63) in MCC is most likely functionally driven as a compensatory response to defective p53 tumor suppressor activity. •In Merkel cell carcinoma (MCC), p63 expression is associated with a poor prognosis.•The proapoptotic TAp63 isoform of the protein predominates in MCC.•p63 expression in MCC correlates with increased/aberrant p53 expression.•p63 expression in MCC correlates with TP53 mutation.•p63 may be a functional marker of a disordered TP53/p53 system in MCC.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>34391748</pmid><doi>10.1016/j.humpath.2021.08.003</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-2841-8057</orcidid><orcidid>https://orcid.org/0000-0002-9246-4317</orcidid><orcidid>https://orcid.org/0000-0003-3205-0216</orcidid><orcidid>https://orcid.org/0000-0002-7363-3509</orcidid><orcidid>https://orcid.org/0000-0001-7586-9008</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0046-8177
ispartof Human pathology, 2021-11, Vol.117, p.31-41
issn 0046-8177
1532-8392
language eng
recordid cdi_proquest_miscellaneous_2561918432
source MEDLINE; ScienceDirect Journals (5 years ago - present)
subjects Aged
Aged, 80 and over
Bioinformatics
Cancer
Carcinoma, Merkel Cell - genetics
Carcinoma, Merkel Cell - metabolism
Carcinoma, Merkel Cell - pathology
Cell cycle
Female
Humans
Male
Medical prognosis
Merkel cell carcinoma
Middle Aged
Morphology
Mutation
Next-generation sequencing
p53
p63
Protein expression
Protein Isoforms
Proteins
Skin cancer
Skin Neoplasms - genetics
Skin Neoplasms - metabolism
Skin Neoplasms - pathology
TP53
TP63
Transcription Factors - biosynthesis
Transcription Factors - genetics
Tumor Suppressor Protein p53 - biosynthesis
Tumor Suppressor Protein p53 - genetics
Tumor Suppressor Proteins - biosynthesis
Tumor Suppressor Proteins - genetics
Tumors
Variables
title Relationship between p63 and p53 expression in Merkel cell carcinoma and corresponding abnormalities in TP63 and TP53: a study and a proposal
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T19%3A08%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Relationship%20between%20p63%20and%20p53%20expression%20in%20Merkel%20cell%20carcinoma%20and%20corresponding%20abnormalities%20in%20TP63%20and%20TP53:%20a%20study%20and%20a%20proposal&rft.jtitle=Human%20pathology&rft.au=DeCoste,%20Ryan%20C.&rft.date=2021-11&rft.volume=117&rft.spage=31&rft.epage=41&rft.pages=31-41&rft.issn=0046-8177&rft.eissn=1532-8392&rft_id=info:doi/10.1016/j.humpath.2021.08.003&rft_dat=%3Cproquest_cross%3E2580329580%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2580329580&rft_id=info:pmid/34391748&rft_els_id=S0046817721001453&rfr_iscdi=true